Bispecific Antibody Market Report

Japan Bispecific Antibody Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Sep 16, 2019
  • PAGES：139
  • REPORT CODE：GMM258263
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan Bispecific Antibody market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan Bispecific Antibody market. Detailed analysis of key players, along with key growth strategies adopted by Bispecific Antibody industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.


    By Player:

    • Regeneron Pharmaceuticals

    • Affimed Therapeutics

    • Neovii Biotech

    • Amgen

    • Roche

    • EMD Serono

    • Merus

    • Genmab

    • Immunomedics

    • Ablynx

    • AstraZeneca (MedImmune)

    • MacroGenics

    • NovImmune SA

    • Emergent BioSolutions

    • Eli Lilly

    • Genentech

    • OncoMed Pharmaceuticals

    • Jounce Therapeutics

    • Adimab

    • Chugai Pharmaceutical

    • Pieris

    • Sanofi


    By Type:

    • Catumaxomab (Removab)

    • Blinatumomab

    • Duligotumab

    • SAR 156597


    By End-User:

    • BsMAb for Diagnosis of Infectious Diseases

    • Diagnosis of Bacterial Infections

    • Diagnosis of Viral Infections

    • BsMAb for Cancer Diagnostic

    • BsAbs Blocking Signaling Pathways

    • BsAbs Targeting Tumor Angiogenesis

    • Specific Delivery of Effector Compounds to Targets

    • Bispecific Antibodies & Gene Therapy


    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Bispecific Antibody Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan Bispecific Antibody Market Size and Growth Rate of Catumaxomab (Removab) from 2014 to 2026

      • 1.3.2 Japan Bispecific Antibody Market Size and Growth Rate of Blinatumomab from 2014 to 2026

      • 1.3.3 Japan Bispecific Antibody Market Size and Growth Rate of Duligotumab from 2014 to 2026

      • 1.3.4 Japan Bispecific Antibody Market Size and Growth Rate of SAR 156597 from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Japan Bispecific Antibody Market Size and Growth Rate of BsMAb for Diagnosis of Infectious Diseases from 2014 to 2026

      • 1.4.2 Japan Bispecific Antibody Market Size and Growth Rate of Diagnosis of Bacterial Infections from 2014 to 2026

      • 1.4.3 Japan Bispecific Antibody Market Size and Growth Rate of Diagnosis of Viral Infections from 2014 to 2026

      • 1.4.4 Japan Bispecific Antibody Market Size and Growth Rate of BsMAb for Cancer Diagnostic from 2014 to 2026

      • 1.4.5 Japan Bispecific Antibody Market Size and Growth Rate of BsAbs Blocking Signaling Pathways from 2014 to 2026

      • 1.4.6 Japan Bispecific Antibody Market Size and Growth Rate of BsAbs Targeting Tumor Angiogenesis from 2014 to 2026

      • 1.4.7 Japan Bispecific Antibody Market Size and Growth Rate of Specific Delivery of Effector Compounds to Targets from 2014 to 2026

      • 1.4.8 Japan Bispecific Antibody Market Size and Growth Rate of Bispecific Antibodies & Gene Therapy from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026


    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants


    3 Segmentation of Bispecific Antibody Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Bispecific Antibody by Major Types

      • 3.4.1 Market Size and Growth Rate of Catumaxomab (Removab)

      • 3.4.2 Market Size and Growth Rate of Blinatumomab

      • 3.4.3 Market Size and Growth Rate of Duligotumab

      • 3.4.4 Market Size and Growth Rate of SAR 156597

    4 Segmentation of Bispecific Antibody Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Bispecific Antibody by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Bispecific Antibody in BsMAb for Diagnosis of Infectious Diseases

      • 4.4.2 Market Size and Growth Rate of Bispecific Antibody in Diagnosis of Bacterial Infections

      • 4.4.3 Market Size and Growth Rate of Bispecific Antibody in Diagnosis of Viral Infections

      • 4.4.4 Market Size and Growth Rate of Bispecific Antibody in BsMAb for Cancer Diagnostic

      • 4.4.5 Market Size and Growth Rate of Bispecific Antibody in BsAbs Blocking Signaling Pathways

      • 4.4.6 Market Size and Growth Rate of Bispecific Antibody in BsAbs Targeting Tumor Angiogenesis

      • 4.4.7 Market Size and Growth Rate of Bispecific Antibody in Specific Delivery of Effector Compounds to Targets

      • 4.4.8 Market Size and Growth Rate of Bispecific Antibody in Bispecific Antibodies & Gene Therapy


    5 Market Analysis by Regions

    • 5.1 Japan Bispecific Antibody Production Analysis by Regions

    • 5.2 Japan Bispecific Antibody Consumption Analysis by Regions


    6 Hokkaido Bispecific Antibody Landscape Analysis

    • 6.1 Hokkaido Bispecific Antibody Landscape Analysis by Major Types

    • 6.2 Hokkaido Bispecific Antibody Landscape Analysis by Major End-Users


    7 Tohoku Bispecific Antibody Landscape Analysis

    • 7.1 Tohoku Bispecific Antibody Landscape Analysis by Major Types

    • 7.2 Tohoku Bispecific Antibody Landscape Analysis by Major End-Users


    8 Kanto Bispecific Antibody Landscape Analysis

    • 8.1 Kanto Bispecific Antibody Landscape Analysis by Major Types

    • 8.2 Kanto Bispecific Antibody Landscape Analysis by Major End-Users


    9 Chubu Bispecific Antibody Landscape Analysis

    • 9.1 Chubu Bispecific Antibody Landscape Analysis by Major Types

    • 9.2 Chubu Bispecific Antibody Landscape Analysis by Major End-Users


    10 Kinki Bispecific Antibody Landscape Analysis

    • 10.1 Kinki Bispecific Antibody Landscape Analysis by Major Types

    • 10.2 Kinki Bispecific Antibody Landscape Analysis by Major End-Users


    11 Chugoku Bispecific Antibody Landscape Analysis

    • 11.1 Chugoku Bispecific Antibody Landscape Analysis by Major Types

    • 11.2 Chugoku Bispecific Antibody Landscape Analysis by Major End-Users


    12 Shikoku Bispecific Antibody Landscape Analysis

    • 12.1 Shikoku Bispecific Antibody Landscape Analysis by Major Types

    • 12.2 Shikoku Bispecific Antibody Landscape Analysis by Major End-Users


    13 Kyushu Bispecific Antibody Landscape Analysis

    • 13.1 Kyushu Bispecific Antibody Landscape Analysis by Major Types

    • 13.2 Kyushu Bispecific Antibody Landscape Analysis by Major End-Users


    14 Major Players Profiles

    • 14.1 Regeneron Pharmaceuticals

      • 14.1.1 Regeneron Pharmaceuticals Company Profile and Recent Development

      • 14.1.2 Market Performance

      • 14.1.3 Product and Service Introduction

    • 14.2 Affimed Therapeutics

      • 14.2.1 Affimed Therapeutics Company Profile and Recent Development

      • 14.2.2 Market Performance

      • 14.2.3 Product and Service Introduction

    • 14.3 Neovii Biotech

      • 14.3.1 Neovii Biotech Company Profile and Recent Development

      • 14.3.2 Market Performance

      • 14.3.3 Product and Service Introduction

    • 14.4 Amgen

      • 14.4.1 Amgen Company Profile and Recent Development

      • 14.4.2 Market Performance

      • 14.4.3 Product and Service Introduction

    • 14.5 Roche

      • 14.5.1 Roche Company Profile and Recent Development

      • 14.5.2 Market Performance

      • 14.5.3 Product and Service Introduction

    • 14.6 EMD Serono

      • 14.6.1 EMD Serono Company Profile and Recent Development

      • 14.6.2 Market Performance

      • 14.6.3 Product and Service Introduction

    • 14.7 Merus

      • 14.7.1 Merus Company Profile and Recent Development

      • 14.7.2 Market Performance

      • 14.7.3 Product and Service Introduction

    • 14.8 Genmab

      • 14.8.1 Genmab Company Profile and Recent Development

      • 14.8.2 Market Performance

      • 14.8.3 Product and Service Introduction

    • 14.9 Immunomedics

      • 14.9.1 Immunomedics Company Profile and Recent Development

      • 14.9.2 Market Performance

      • 14.9.3 Product and Service Introduction

    • 14.10 Ablynx

      • 14.10.1 Ablynx Company Profile and Recent Development

      • 14.10.2 Market Performance

      • 14.10.3 Product and Service Introduction

    • 14.11 AstraZeneca (MedImmune)

      • 14.11.1 AstraZeneca (MedImmune) Company Profile and Recent Development

      • 14.11.2 Market Performance

      • 14.11.3 Product and Service Introduction

    • 14.12 MacroGenics

      • 14.12.1 MacroGenics Company Profile and Recent Development

      • 14.12.2 Market Performance

      • 14.12.3 Product and Service Introduction

    • 14.13 NovImmune SA

      • 14.13.1 NovImmune SA Company Profile and Recent Development

      • 14.13.2 Market Performance

      • 14.13.3 Product and Service Introduction

    • 14.14 Emergent BioSolutions

      • 14.14.1 Emergent BioSolutions Company Profile and Recent Development

      • 14.14.2 Market Performance

      • 14.14.3 Product and Service Introduction

    • 14.15 Eli Lilly

      • 14.15.1 Eli Lilly Company Profile and Recent Development

      • 14.15.2 Market Performance

      • 14.15.3 Product and Service Introduction

    • 14.16 Genentech

      • 14.16.1 Genentech Company Profile and Recent Development

      • 14.16.2 Market Performance

      • 14.16.3 Product and Service Introduction

    • 14.17 OncoMed Pharmaceuticals

      • 14.17.1 OncoMed Pharmaceuticals Company Profile and Recent Development

      • 14.17.2 Market Performance

      • 14.17.3 Product and Service Introduction

    • 14.18 Jounce Therapeutics

      • 14.18.1 Jounce Therapeutics Company Profile and Recent Development

      • 14.18.2 Market Performance

      • 14.18.3 Product and Service Introduction

    • 14.19 Adimab

      • 14.19.1 Adimab Company Profile and Recent Development

      • 14.19.2 Market Performance

      • 14.19.3 Product and Service Introduction

    • 14.20 Chugai Pharmaceutical

      • 14.20.1 Chugai Pharmaceutical Company Profile and Recent Development

      • 14.20.2 Market Performance

      • 14.20.3 Product and Service Introduction

    • 14.21 Pieris

      • 14.21.1 Pieris Company Profile and Recent Development

      • 14.21.2 Market Performance

      • 14.21.3 Product and Service Introduction

    • 14.22 Sanofi

      • 14.22.1 Sanofi Company Profile and Recent Development

      • 14.22.2 Market Performance

      • 14.22.3 Product and Service Introduction

     

    The List of Tables and Figures (Totals 98 Figures and 150 Tables)

     

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Catumaxomab (Removab) from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Blinatumomab from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Duligotumab from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of SAR 156597 from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsMAb for Diagnosis of Infectious Diseases from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Diagnosis of Bacterial Infections from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Diagnosis of Viral Infections from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsMAb for Cancer Diagnostic from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsAbs Blocking Signaling Pathways from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsAbs Targeting Tumor Angiogenesis from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Specific Delivery of Effector Compounds to Targets from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Bispecific Antibodies & Gene Therapy from 2014 to 2026

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu Bispecific Antibody Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Bispecific Antibody Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Bispecific Antibody

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Bispecific Antibody by Different Types from 2014 to 2026

    • Table Consumption Share of Bispecific Antibody by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Catumaxomab (Removab)

    • Figure Market Size and Growth Rate of Blinatumomab

    • Figure Market Size and Growth Rate of Duligotumab

    • Figure Market Size and Growth Rate of SAR 156597

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Bispecific Antibody by Different End-Users from 2014 to 2026

    • Table Consumption Share of Bispecific Antibody by Different End-Users from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsMAb for Diagnosis of Infectious Diseases from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Diagnosis of Bacterial Infections from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Diagnosis of Viral Infections from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsMAb for Cancer Diagnostic from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsAbs Blocking Signaling Pathways from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of BsAbs Targeting Tumor Angiogenesis from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Specific Delivery of Effector Compounds to Targets from 2014 to 2026

    • Figure Japan Bispecific Antibody Market Size and Growth Rate of Bispecific Antibodies & Gene Therapy from 2014 to 2026

    • Table Japan Bispecific Antibody Production by Regions

    • Table Japan Bispecific Antibody Production Share by Regions

    • Figure Japan Bispecific Antibody Production Share by Regions in 2014

    • Figure Japan Bispecific Antibody Production Share by Regions in 2018

    • Figure Japan Bispecific Antibody Production Share by Regions in 2026

    • Table Japan Bispecific Antibody Consumption by Regions

    • Table Japan Bispecific Antibody Consumption Share by Regions

    • Figure Japan Bispecific Antibody Consumption Share by Regions in 2014

    • Figure Japan Bispecific Antibody Consumption Share by Regions in 2018

    • Figure Japan Bispecific Antibody Consumption Share by Regions in 2026

    • Table Hokkaido Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Hokkaido Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido Bispecific Antibody Consumption Share by Types in 2014

    • Figure Hokkaido Bispecific Antibody Consumption Share by Types in 2018

    • Figure Hokkaido Bispecific Antibody Consumption Share by Types in 2026

    • Table Hokkaido Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Hokkaido Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Hokkaido Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Hokkaido Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Tohoku Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Tohoku Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Tohoku Bispecific Antibody Consumption Share by Types in 2014

    • Figure Tohoku Bispecific Antibody Consumption Share by Types in 2018

    • Figure Tohoku Bispecific Antibody Consumption Share by Types in 2026

    • Table Tohoku Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Tohoku Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Tohoku Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Tohoku Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Kanto Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Kanto Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Kanto Bispecific Antibody Consumption Share by Types in 2014

    • Figure Kanto Bispecific Antibody Consumption Share by Types in 2018

    • Figure Kanto Bispecific Antibody Consumption Share by Types in 2026

    • Table Kanto Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Kanto Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Kanto Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Kanto Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Chubu Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Chubu Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Chubu Bispecific Antibody Consumption Share by Types in 2014

    • Figure Chubu Bispecific Antibody Consumption Share by Types in 2018

    • Figure Chubu Bispecific Antibody Consumption Share by Types in 2026

    • Table Chubu Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Chubu Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Chubu Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Chubu Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Kinki Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Kinki Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Kinki Bispecific Antibody Consumption Share by Types in 2014

    • Figure Kinki Bispecific Antibody Consumption Share by Types in 2018

    • Figure Kinki Bispecific Antibody Consumption Share by Types in 2026

    • Table Kinki Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Kinki Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Kinki Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Kinki Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Chugoku Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Chugoku Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Chugoku Bispecific Antibody Consumption Share by Types in 2014

    • Figure Chugoku Bispecific Antibody Consumption Share by Types in 2018

    • Figure Chugoku Bispecific Antibody Consumption Share by Types in 2026

    • Table Chugoku Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Chugoku Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Chugoku Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Chugoku Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Shikoku Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Shikoku Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Shikoku Bispecific Antibody Consumption Share by Types in 2014

    • Figure Shikoku Bispecific Antibody Consumption Share by Types in 2018

    • Figure Shikoku Bispecific Antibody Consumption Share by Types in 2026

    • Table Shikoku Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Shikoku Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Shikoku Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Shikoku Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Kyushu Bispecific Antibody Consumption by Types from 2014 to 2026

    • Table Kyushu Bispecific Antibody Consumption Share by Types from 2014 to 2026

    • Figure Kyushu Bispecific Antibody Consumption Share by Types in 2014

    • Figure Kyushu Bispecific Antibody Consumption Share by Types in 2018

    • Figure Kyushu Bispecific Antibody Consumption Share by Types in 2026

    • Table Kyushu Bispecific Antibody Consumption by End-Users from 2014 to 2026

    • Table Kyushu Bispecific Antibody Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu Bispecific Antibody Consumption Share by End-Users in 2014

    • Figure Kyushu Bispecific Antibody Consumption Share by End-Users in 2018

    • Figure Kyushu Bispecific Antibody Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of Regeneron Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Regeneron Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Regeneron Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Regeneron Pharmaceuticals

    • Table Product and Service Introduction of Regeneron Pharmaceuticals

    • Table Company Profile and Development Status of Affimed Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Affimed Therapeutics

    • Figure Sales and Growth Rate Analysis of Affimed Therapeutics

    • Figure Revenue and Market Share Analysis of Affimed Therapeutics

    • Table Product and Service Introduction of Affimed Therapeutics

    • Table Company Profile and Development Status of Neovii Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Neovii Biotech

    • Figure Sales and Growth Rate Analysis of Neovii Biotech

    • Figure Revenue and Market Share Analysis of Neovii Biotech

    • Table Product and Service Introduction of Neovii Biotech

    • Table Company Profile and Development Status of Amgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen

    • Figure Sales and Growth Rate Analysis of Amgen

    • Figure Revenue and Market Share Analysis of Amgen

    • Table Product and Service Introduction of Amgen

    • Table Company Profile and Development Status of Roche

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche

    • Figure Sales and Growth Rate Analysis of Roche

    • Figure Revenue and Market Share Analysis of Roche

    • Table Product and Service Introduction of Roche

    • Table Company Profile and Development Status of EMD Serono

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of EMD Serono

    • Figure Sales and Growth Rate Analysis of EMD Serono

    • Figure Revenue and Market Share Analysis of EMD Serono

    • Table Product and Service Introduction of EMD Serono

    • Table Company Profile and Development Status of Merus

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merus

    • Figure Sales and Growth Rate Analysis of Merus

    • Figure Revenue and Market Share Analysis of Merus

    • Table Product and Service Introduction of Merus

    • Table Company Profile and Development Status of Genmab

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genmab

    • Figure Sales and Growth Rate Analysis of Genmab

    • Figure Revenue and Market Share Analysis of Genmab

    • Table Product and Service Introduction of Genmab

    • Table Company Profile and Development Status of Immunomedics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Immunomedics

    • Figure Sales and Growth Rate Analysis of Immunomedics

    • Figure Revenue and Market Share Analysis of Immunomedics

    • Table Product and Service Introduction of Immunomedics

    • Table Company Profile and Development Status of Ablynx

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ablynx

    • Figure Sales and Growth Rate Analysis of Ablynx

    • Figure Revenue and Market Share Analysis of Ablynx

    • Table Product and Service Introduction of Ablynx

    • Table Company Profile and Development Status of AstraZeneca (MedImmune)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AstraZeneca (MedImmune)

    • Figure Sales and Growth Rate Analysis of AstraZeneca (MedImmune)

    • Figure Revenue and Market Share Analysis of AstraZeneca (MedImmune)

    • Table Product and Service Introduction of AstraZeneca (MedImmune)

    • Table Company Profile and Development Status of MacroGenics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of MacroGenics

    • Figure Sales and Growth Rate Analysis of MacroGenics

    • Figure Revenue and Market Share Analysis of MacroGenics

    • Table Product and Service Introduction of MacroGenics

    • Table Company Profile and Development Status of NovImmune SA

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of NovImmune SA

    • Figure Sales and Growth Rate Analysis of NovImmune SA

    • Figure Revenue and Market Share Analysis of NovImmune SA

    • Table Product and Service Introduction of NovImmune SA

    • Table Company Profile and Development Status of Emergent BioSolutions

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Emergent BioSolutions

    • Figure Sales and Growth Rate Analysis of Emergent BioSolutions

    • Figure Revenue and Market Share Analysis of Emergent BioSolutions

    • Table Product and Service Introduction of Emergent BioSolutions

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of Genentech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Genentech

    • Figure Sales and Growth Rate Analysis of Genentech

    • Figure Revenue and Market Share Analysis of Genentech

    • Table Product and Service Introduction of Genentech

    • Table Company Profile and Development Status of OncoMed Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of OncoMed Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of OncoMed Pharmaceuticals

    • Figure Revenue and Market Share Analysis of OncoMed Pharmaceuticals

    • Table Product and Service Introduction of OncoMed Pharmaceuticals

    • Table Company Profile and Development Status of Jounce Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Jounce Therapeutics

    • Figure Sales and Growth Rate Analysis of Jounce Therapeutics

    • Figure Revenue and Market Share Analysis of Jounce Therapeutics

    • Table Product and Service Introduction of Jounce Therapeutics

    • Table Company Profile and Development Status of Adimab

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Adimab

    • Figure Sales and Growth Rate Analysis of Adimab

    • Figure Revenue and Market Share Analysis of Adimab

    • Table Product and Service Introduction of Adimab

    • Table Company Profile and Development Status of Chugai Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Chugai Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Chugai Pharmaceutical

    • Figure Revenue and Market Share Analysis of Chugai Pharmaceutical

    • Table Product and Service Introduction of Chugai Pharmaceutical

    • Table Company Profile and Development Status of Pieris

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pieris

    • Figure Sales and Growth Rate Analysis of Pieris

    • Figure Revenue and Market Share Analysis of Pieris

    • Table Product and Service Introduction of Pieris

    • Table Company Profile and Development Status of Sanofi

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

    • Figure Sales and Growth Rate Analysis of Sanofi

    • Figure Revenue and Market Share Analysis of Sanofi

    • Table Product and Service Introduction of Sanofi

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US